Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Interim Trading Statement

19 Jul 2012 07:00

RNS Number : 9983H
Biome Technologies PLC
19 July 2012
 



19 July 2012

 

Biome Technologies plc ("Biome", "the Company" or "the Group")

 

Interim Trading Statement

 

 

Biome Technologies plc, the bioplastics and RF technology business, is pleased to announce a trading update, ahead of its Interim Results for the six-month period ended 30 June 2012, which are expected to be announced on 3 September 2012.

 

Total Group revenues achieved in the first half of 2012 were £7.5m, down 28% on the same period in 2011. In the Trading Update of 31 May, it was stated that sales within the Bioplastics Division for April and May were markedly below our expectations following legislative changes in Italy and wider disruption to the supply and demand balance in Europe. This is reflected in the second quarter, with Group revenues of £2.9m (Q2 2011: £4.9m), 38% below the revenues of £4.6m achieved in the first quarter.

 

The Bioplastics Division saw revenues drop from £4.3m in Q1 to £2.2m in the second quarter (Q2 2011: £3.9m). Within this, Biotec was most adversely affected with revenues down 58% from £3.0m in Q1 to £1.2m in the second quarter (Q2 2011: £1.8m) as third-party sales were depressed due to the previously reported demand changes in southern Europe. In Biome Bioplastics, revenues were down a more modest 26% to £1.0m in the second quarter compared to £1.3m in Q1 (Q2 2011: £2.2m) with some evidence that the broader application base and geographic diversity is providing greater resilience to the current turbulence in the market.

 

The Stanelco RF Technologies Division continues to perform as expected with revenues of £0.7m in Q2, up 95% compared to the first quarter (Q2 2011: £0.9m). The pipeline for fibre optic furnace systems and associated spares continues to grow; orders for nine units to the value of £1.2m have been received and are under build for the second half, with further orders pending. Diversification into new industrial markets continues and the Durapipe UK project is progressing well with the first prototype unit expected to be delivered shortly.

 

The Group's cash position at 30 June 2012 was £1.1m (30 April 2012: £1.5m). Following the period end, the Group announced that Biotec had entered into a €1.5m loan agreement with Sparkasse Emmerich and that €255k in repayment and interest had been repaid to Biome under the shareholder agreement. The Group's secured debt facility of up to £2m with Fortis Commercial Finance remains available but is currently not utilised.

 

The Board continues to believe that these market developments constitute a pause in a fast developing market and that the drivers of requirements for biodegradable and bio-based materials will grow with time.

 

With respect to the patent litigation, updated on 12 July, the recent positive findings in the Court of Turin in the context of other court findings provide further confidence in the value and potential of the Group's technology Biome is well placed and continues to expedite new product development with a focus on those opportunities likely to yield growth in the shorter term. Actions to reduce costs by around by £0.6m on an annualised basis have now been completed and the benefits will build in the second half. The Group is trading in-line with the Board's revised expectations.

 

-Ends-

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com Tel: +44 (0) 2380 867 100

 

Daniel Stewart & Company plc

David Hart/Jamie Barklem

www.danielstewart.co.uk Tel: +44 (0) 20 7776 6550

 

First Columbus

Chris Crawford/Kelly Gardiner

www.first-columbus.com Tel: +44 (0) 20 3002 2070

 

FTI Consulting

Oliver Winters/Latika Shah Tel: +44 (0) 20 7831 3113

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSFWFWAFESEEW
Date   Source Headline
27th Apr 20071:34 pmRNSResult of AGM
27th Apr 20071:32 pmRNSDirectorate Change
26th Apr 20071:42 pmRNSAnnual Information Update
13th Apr 200712:29 pmRNSDirector's Dealing
30th Mar 20071:32 pmRNSAnnual Report and Accounts
23rd Mar 20075:09 pmRNSNotifiable Interest
21st Mar 20077:03 amRNSPreliminary Results
14th Mar 20075:59 pmRNSHolding(s) in Company
26th Feb 20077:01 amRNSBoard Appointment
23rd Feb 20073:18 pmRNSHolding(s) in Company
30th Jan 20079:00 amRNSNotice of Results
18th Dec 20064:58 pmRNSTotal Voting Rights
8th Dec 200612:31 pmRNSNotifiable Interest
28th Nov 20063:32 pmRNSNotifiable Interest
17th Nov 20063:33 pmRNSNotifiable Interest
16th Nov 20069:02 amRNSNotifiable Interest
14th Nov 20064:37 pmRNSDirectorate Change
14th Nov 20064:09 pmRNSDirector/PDMR Shareholding
14th Nov 20064:03 pmRNSNotifiable Interest
14th Nov 20069:55 amRNSNotifiable Interest
10th Nov 200610:29 amRNSHolding(s) in Company
9th Nov 200611:45 amRNSNotifiable Interest
8th Nov 20063:08 pmRNSNotifiable Interest
7th Nov 20068:01 amRNSIssue of Equity
6th Nov 200612:12 pmRNSResult of EGM
3rd Nov 20064:41 pmRNSNotifiable Interest
3rd Nov 20061:17 pmRNSOpen Offer Result - Amendment
2nd Nov 20066:03 pmRNSOpen Offer Result
31st Oct 200611:54 amRNSNotifiable Interest
17th Oct 20065:54 pmRNSNotifiable Interest
17th Oct 200610:44 amRNSNotifiable Interest
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.